SCHEMBL4485390

SCHEMBL4485390

Cc1c[nH]c2cc(OCc3ccccc3)c(-c3n[nH]cc3N3CCN(C(=O)OCc4ccccc4)CC3)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TMEM97 Q5BJF2 7/20 0.39
▸ SIGMAR1 Q99720 7/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ ADRA2C P18825 1/20 0.39
▸ DRD1 P21728 1/20 0.39
▸ HRH2 P25021 1/20 0.39
▸ HTR1B P28222 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ HTR1E P28566 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39
▸ MGLL Q99685 1/20 0.37
▸ HTR6 P50406 3/20 0.37
▸ KCNH2 Q12809 3/20 0.37
▸ TLR9 Q9NR96 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13637514 0.93 ADORA2B (0.38) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL4484231 0.80 CYP11B1 (0.51) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL4477826 0.77 ALDH1A1 (0.49) MEN1KMT2ASMN1; SMN2
SCHEMBL4492498 0.76 TLR9 (0.47) TLR9TLR7FLT3
SCHEMBL4472766 0.74 CCNT1 (0.56) TLR9TLR7FLT3MEN1KMT2A
SCHEMBL4483426 0.74 ALDH1A1 (0.38) MEN1KMT2ANPSR1SMN1; SMN2GAA
SCHEMBL4483424 0.74 ALDH1A1 (0.38) MEN1KMT2ANPSR1SMN1; SMN2GAA
SCHEMBL31134492 0.74 ALDH1A1 (0.51) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL13637519 0.74 CYP11B1 (0.43) TMEM97SIGMAR1HTR1AADRA2AADRA2B
SCHEMBL13637509 0.71 ALDH1A1 (0.49) SIGMAR1HRH2HTR2AHRH1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612201-B2 Pyrazole compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2009-11-03 — — US disclosed
US-7612201-B2 Pyrazole compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2009-11-03 — — US disclosed
US-20060148817-A1 Pyrazole compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2006-07-06 — — US disclosed
EP-1572664-A1 PYRAZOLE COMPOUNDS Vernalis (Cambridge) Limited (GB) 2005-09-14 — — EP disclosed
WO-2004056782-A1 PYRAZOLE COMPOUNDS VERNALIS (CAMBRIDGE) LIMITED (GB) 2004-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148817-A1 Pyrazole compounds NRAS, HSP90AB1, HSP90AA1 TMEM97 995/4885SIGMAR1 494/4885HTR1A 2452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback